Dimension Therapeutics
About:
Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases.
Twitter/X: dimensiontx
Top Investors: OrbiMed, RA Capital Management, F-Prime Capital, Eight Roads Ventures, Rock Springs Capital
Description:
Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.
$125M
$10M to $50M
Cambridge, Massachusetts, United States
2013-01-01
info(AT)dimensiontx.com
Allan M. Fox, Ben Auspitz, Kenneth T. Mills
51-100
2015-04-21
Delisted
© 2025 bioDAO.ai